Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- manufacturers
- OSU-53
-
- $1670.00
-
2026-07-27
- CAS:1290069-19-0
- Purity:
- Supply Ability: 10g
|
| | Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- Basic information |
| | Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- Chemical Properties |
| Boiling point | 690.5±65.0 °C(Predicted) | | density | 1.484±0.06 g/cm3(Predicted) | | pka | 5.43±0.10(Predicted) |
| | Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- Usage And Synthesis |
| Uses | OSU-53 is an orally active AMPK activator (EC50: 0.3 μM) and a direct mTOR inhibitor. OSU-53 induces autophagy and increases conversion of LC3 I to LC3 II. OSU-53 also modulates energy homeostasis by suppressing fatty acid biosynthesis and shifting the metabolism to oxidation by up-regulating the expression of PGC1α and NRF-1. OSU-53 has antitumor activity in various tumor models, such as breast cancer and thyroid cancer[1][2]. | | References | [1] Plews RL, et al. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100(5):E748-56. DOI:10.1210/jc.2014-1777
[2] Lee KH, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011 Nov 11;286(45):39247-58. DOI:10.1074/jbc.M111.264598 |
| | Benzenesulfonamide, N-[4-[(Z)-[3-[(1-methylcyclohexyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenyl]-4-nitro-3-(trifluoromethyl)- Preparation Products And Raw materials |
|